Target Poor or Non Binder(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T02565 | Target Info | |||
| Target Name | Liver organic anion transporter 2 (SLCO1B3) | ||||
| Synonyms |
Solute carrier organic anion transporter family member 1B3; Solute carrier family 21 member 8; SLC21A8; Organic anion-transporting polypeptide 8; Organic anion transporter 8; OATP8; OATP1B3; OATP-8; Liver-specific organic anion transporter 2; LST2; LST-2
Click to Show/Hide
|
||||
| Target Type | Literature-reported Target | ||||
| Gene Name | SLCO1B3 | ||||
| UniProt ID | |||||
| Poor Binders of This Target (in total, 4 binders) | Download | Top | |||
|---|---|---|---|---|---|
| Compound Name |
Pravastatin
Click to Show/Hide
|
Approved | Compound Info | ||
| Synonyms |
Eptastatin; Oliprevin; Pravastatina; Pravastatine; Pravastatinum; Pravator; Vasten; Pravastatin Sodium Salt; Pravastatina [Spanish]; Pravastatine [French]; Pravastatinum [Latin]; KS-5015; Pravachol (TN); Pravastatin (INN); Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravator (TN); RMS-431; Selektine (TN); SQ-31,000; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
Click to Show/Hide
|
||||
| Activity |
Ki = 57000 nM
|
[1] | |||
| Compound Name |
Chlorambucil
Click to Show/Hide
|
Approved | Compound Info | ||
| Synonyms |
Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN)
Click to Show/Hide
|
||||
| Activity |
IC50 = 80700 nM
|
[2] | |||
| Compound Name |
Dolutegravir
Click to Show/Hide
|
Approved | Compound Info | ||
| Synonyms |
1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[3] | |||
| Compound Name |
Combretastatin A4
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
Combretastatin A-4; Combrestatin A4; Combretastatin-A4; Crc 87-09; (Z)-2-METHOXY-5-(3,4,5-TRIMETHOXYSTYRYL)PHENOL; UNII-16U6OP69RQ; NSC 817373; CHEMBL67; NSC-613729; 16U6OP69RQ; MFCD03453309; 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; 2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-; Crc-98-09; Phenol, 2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)ethenyl)-, (Z)-; Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, (Z)-; combretastin A4; Combretastatin 4; Combrestatin A-4; Combretastin A-4; 3,4,5-Trimethoxy-3'-hydroxy-4'-methoxystilbene; Combretastastin A-4; NSC 609397; NSC 613729; 2-methoxy-5-(3,4,5-trimethoxystyryl)phenol; Z-Combretastatin A-4; 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl)ethene; 2'-deoxycombretastatin A1; 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; 2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; SCHEMBL18945; cc-322; combretastatin A-4, (CSA4); GTPL8854; PHE021; AOB1953; HMS3650G11; ACT02766; EX-A4207; HY-N2146; BDBM50005480; s7783; ZINC13452167; AKOS015950727; AC-5280; ACN-028881; CCG-265026; CS-6023; DB14680; DS-5860; MCULE-9118029221; Phenol,4,5-trimethoxyphenyl)ethenyl]-; ST-1986; SC-96865; AB0073032; ST4149439; B6764; Combretastatin A4, >=98% (HPLC), powder; Y0443; 5-(3,4,5-trimethoxystyryl)-2-methoxyphenol; A12601; C20268; 3'-Hydroxy-3,4,4',5-tetramethoxy-cis-stilbene; (Z)-5-(3,4,5-trimethoxystyryl)-2-methoxyphenol; 048C596; SR-01000946784; (Z)-3''-hydroxy-3,4,4'',5-tetramethoxystilbene; Q5150955; SR-01000946784-1; [3,4,5-trimethoxy-3'-hydroxy-4'-methoxy-(z)-stilbene]; 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenol; 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol; 5-[(1Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-2-methoxyphenol; 2-Methoxy-5-[(Z)-2-(3,4,5-trimethox y-phenyl)-vinyl]-phenol; 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenol; (combretastin A-4)2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; 5-[(S)-2-Hydroxy-2-(3,4,5-trimethoxy-phenyl)-ethyl]-2-methoxy-phenol; (combretastatin A-4)2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol
Click to Show/Hide
|
||||
| Activity |
IC50 = 194540 nM
|
[4] | |||
| Non Binders of This Target (in total, 1 non binders) | Download | Top | |||
|---|---|---|---|---|---|
| Compound Name |
(E)-Combretastatin iso A-4
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL454575; (Z)-3',4,4',5'-Tetramethoxystilben-3-yl beta-D-glucopyranoside
Click to Show/Hide
|
||||
| Activity |
IC50 > 200000 nM
|
[4] | |||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. | ||||
| REF 2 | Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31. | ||||
| REF 3 | In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61. | ||||
| REF 4 | Deciphering the origins of molecular toxicity of combretastatin A4 and its glycoconjugates: interactions with major drug transporters and their safety profiles in vitro and in vivo. Medchemcomm. 2017 Jun 12;8(7):1542-1552. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.